Nature Communications (May 2024)

Disentangling oncogenic amplicons in esophageal adenocarcinoma

  • Alvin Wei Tian Ng,
  • Dylan Peter McClurg,
  • Ben Wesley,
  • Shahriar A. Zamani,
  • Emily Black,
  • Ahmad Miremadi,
  • Olivier Giger,
  • Rogier ten Hoopen,
  • Ginny Devonshire,
  • Aisling M. Redmond,
  • Nicola Grehan,
  • Sriganesh Jammula,
  • Adrienn Blasko,
  • Xiaodun Li,
  • Samuel Aparicio,
  • Simon Tavaré,
  • Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium,
  • Karol Nowicki-Osuch,
  • Rebecca C. Fitzgerald

DOI
https://doi.org/10.1038/s41467-024-47619-4
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Esophageal adenocarcinoma is a prominent example of cancer characterized by frequent amplifications in oncogenes. However, the mechanisms leading to amplicons that involve breakage-fusion-bridge cycles and extrachromosomal DNA are poorly understood. Here, we use 710 esophageal adenocarcinoma cases with matched samples and patient-derived organoids to disentangle complex amplicons and their associated mechanisms. Short-read sequencing identifies ERBB2, MYC, MDM2, and HMGA2 as the most frequent oncogenes amplified in extrachromosomal DNAs. We resolve complex extrachromosomal DNA and breakage-fusion-bridge cycles amplicons by integrating of de-novo assemblies and DNA methylation in nine long-read sequenced cases. Complex amplicons shared between precancerous biopsy and late-stage tumor, an enrichment of putative enhancer elements and mobile element insertions are potential drivers of complex amplicons’ origin. We find that patient-derived organoids recapitulate extrachromosomal DNA observed in the primary tumors and single-cell DNA sequencing capture extrachromosomal DNA-driven clonal dynamics across passages. Prospectively, long-read and single-cell DNA sequencing technologies can lead to better prediction of clonal evolution in esophageal adenocarcinoma.